{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:14:16Z","timestamp":1776356056570,"version":"3.51.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004168","name":"Universit\u00e4t zu L\u00fcbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004168","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The association between bullous pemphigoid (BP) and melanoma is yet to be investigated. We aimed to assess assess the bidirectional association between BP and melanoma and to delineate the epidemiological features of patients with both diagnoses. A population-based cohort study was performed comparing BP patients (<jats:italic>n<\/jats:italic>\u2009=\u20093924) with age-, sex- and ethnicity-matched control subjects (<jats:italic>n<\/jats:italic>\u2009=\u200919,280) with regard to incident cases of melanoma. A case\u2013control design was additionally adopted to estimate the risk of BP in individuals with a preexisting diagnosis of melanoma. The prevalence of preexisting melanoma was higher in patients with BP than in control subjects (1.5% vs. 1.0%, respectively; <jats:italic>P<\/jats:italic>\u2009=\u20090.004). A history of melanoma confers a 50% increase in the risk of subsequent BP (OR 1.53; 95% CI 1.14\u20132.06). This risk was higher among males (OR 1.66; 95% CI 1.09\u20132.54) and individuals older than 80\u00a0years (OR 1.63; 95% CI 1.11\u20132.38), and persisted after adjustment for multiple putative confounders including PD-1\/PDL-1 antagonists (adjusted OR 1.53; 95% CI 1.14\u20132.06). Conversely, the risk of melanoma among patients with BP was slightly elevated, but did not reach the level of statistical significance (adjusted HR 1.13; 95% CI 0.73\u20131.74). Patients with a dual diagnosis of BP and melanoma were older at the onset of BP and had lower body mass index. A history of melanoma is associated with a 50% increase in the incidence of subsequent BP. Physicians managing patients with both conditions should be aware of this association. Further research is warranted to reveal the underlying mechanism of these findings.<\/jats:p>","DOI":"10.1007\/s00403-021-02211-4","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T15:03:34Z","timestamp":1615302214000},"page":"77-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Melanoma is associated with an increased risk of bullous pemphigoid: a large population-based longitudinal study"],"prefix":"10.1007","volume":"314","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-9151","authenticated-orcid":false,"given":"Khalaf","family":"Kridin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E.","family":"Hundt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle T.","family":"Amber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana Tzur","family":"Bitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"2211_CR1","doi-asserted-by":"crossref","unstructured":"Kridin K (2018) Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunol Res [Internet]. 2018 Feb 21 [cited 2018 Apr 2] 66(1):6\u201317. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29159697","DOI":"10.1007\/s12026-017-8975-2"},{"issue":"27","key":"2211_CR2","doi-asserted-by":"publisher","first-page":"17784","DOI":"10.1016\/S0021-9258(18)55195-4","volume":"266","author":"D Sawamura","year":"1991","unstructured":"Sawamura D, Li K, Chu ML, Uitto J (1991) Human bullous pemphigoid antigen (BPAG1): amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J Biol Chem 266(27):17784\u201317790","journal-title":"J Biol Chem"},{"key":"2211_CR3","doi-asserted-by":"crossref","unstructured":"Muramatsu K, Ujiie H, Kobayashi I, Nishie W, Izumi K, Ito T et al (2018) Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects. J Allergy Clin Immunol [Internet]. 2018 Apr 26 [cited 2018 May 28]; http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29704593","DOI":"10.1016\/j.jaci.2018.03.014"},{"key":"2211_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","volume":"54","author":"KT Amber","year":"2018","unstructured":"Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L (2018) Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol. 54:26\u201351","journal-title":"Clin Rev Allergy Immunol."},{"key":"2211_CR5","doi-asserted-by":"crossref","unstructured":"Kridin K, Ludwig RJ (2018) The growing incidence of Bullous pemphigoid: overview and potential explanations. Front Med [Internet]. 2018 Aug 20 [cited 2018 Sep 11];5(AUG):220. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30177969","DOI":"10.3389\/fmed.2018.00220"},{"key":"2211_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3389\/fmed.2020.00511","volume":"7","author":"K Kridin","year":"2020","unstructured":"Kridin K, Ludwig RJ, Schonmann Y, Damiani G, Cohen AD (2020) The bidirectional association between bullous pemphigoid and psoriasis: a population-based cohort study. Front Med 7:511. https:\/\/doi.org\/10.3389\/fmed.2020.00511","journal-title":"Front Med"},{"key":"2211_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A et al (2018) Melanoma. Lancet 392:971\u2013984","journal-title":"Lancet"},{"key":"2211_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jaad.2018.08.051","volume":"80","author":"RRZ Conic","year":"2019","unstructured":"Conic RRZ, Ko J, Damiani G, Funchain P, Knackstedt T, Vij A et al (2019) Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database. J Am Acad Dermatol. 80:441\u2013447","journal-title":"J Am Acad Dermatol."},{"key":"2211_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp252","author":"RM MacKie","year":"2009","unstructured":"MacKie RM, Hauschild A, Eggermont AMM (2009) Epidemiology of invasive cutaneous melanoma. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdp252","journal-title":"Ann Oncol"},{"key":"2211_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/CMR.0000000000000307","volume":"27","author":"KT Amber","year":"2017","unstructured":"Amber KT, Panganiban CM, Korta D, De Feraudy S, Kelly KM, Grando SA (2017) A case report of bullous pemphigoid associated with a melanoma and review of the literature. Melanoma Res 27:65\u201367","journal-title":"Melanoma Res"},{"issue":"4","key":"2211_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00418-012-0981-9","volume":"138","author":"T Krenacs","year":"2012","unstructured":"Krenacs T, Kiszner G, Stelkovics E, Balla P, Teleki I, Nemeth I et al (2012) Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis. Histochem Cell Biol 138(4):653\u2013667","journal-title":"Histochem Cell Biol"},{"issue":"50","key":"2211_CR12","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1038\/s41388-019-0961-9","volume":"38","author":"BJ Hwang","year":"2019","unstructured":"Hwang BJ, Zhang Y, Brozowski JM, Liu Z, Burette S, Lough K et al (2019) The dysfunction of BP180\/collagen XVII in keratinocytes promotes melanoma progression. Oncogene 38(50):7491\u20137503","journal-title":"Oncogene"},{"issue":"5","key":"2211_CR13","doi-asserted-by":"publisher","first-page":"e10566","DOI":"10.1371\/journal.pone.0010566","volume":"5","author":"T Shimbo","year":"2010","unstructured":"Shimbo T, Tanemura A, Yamazaki T, Tamai K, Katayama I, Kaneda Y (2010) Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma. PLoS ONE 5(5):e10566","journal-title":"PLoS ONE"},{"key":"2211_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/oxfordjournals.aje.a113439","volume":"116","author":"S Greenland","year":"1982","unstructured":"Greenland S, Thomas DC (1982) On the need for the rare disease assumption in case-control studies. Am J Epidemiol. 116:547\u2013553","journal-title":"Am J Epidemiol."},{"key":"2211_CR15","first-page":"204","volume":"149","author":"AD Cohen","year":"2010","unstructured":"Cohen AD, Dreiher J, Regev-Rosenberg S, Yakovson O, Lieberman N, Goldfracht M et al (2010) The quality indigators program in Clalit Health Services: the first decade. Harefuah 149:204\u2013209","journal-title":"Harefuah"},{"key":"2211_CR16","doi-asserted-by":"crossref","unstructured":"Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L (2018) A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol [Internet]. 2018 Jun [cited 2018 May 29];57(6):664\u20139. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29630716","DOI":"10.1111\/ijd.13984"},{"issue":"12","key":"2211_CR17","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/jdv.13660","volume":"30","author":"Y Lai","year":"2016","unstructured":"Lai Y, Yew Y, Lambert W (2016) Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol [Internet] 30(12):2007\u20132015. https:\/\/doi.org\/10.1111\/jdv.13660","journal-title":"J Eur Acad Dermatol Venereol [Internet]"},{"key":"2211_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40035-015-0044-y","volume":"4","author":"P Huang","year":"2015","unstructured":"Huang P, Yang XD, Di Chen S, Xiao Q (2015) The association between Parkinson\u2019s disease and melanoma: a systematic review and meta-analysis. Translational Neurodegeneration 4:21. https:\/\/doi.org\/10.1186\/s40035-015-0044-y","journal-title":"Translational Neurodegeneration"},{"issue":"3","key":"2211_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/003591576105400315","volume":"54","author":"JM Marks","year":"1961","unstructured":"Marks JM, Gold SC (1961) Pemphigoid with malignant melanoma. J R Soc Med 54(3):225\u2013226","journal-title":"J R Soc Med"},{"issue":"4","key":"2211_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/bjc.1968.79","volume":"22","author":"RL Parsons","year":"1968","unstructured":"Parsons RL, Savin JA (1968) Pemphigoid and malignancy. Br J Cancer 22(4):669\u2013672","journal-title":"Br J Cancer"},{"issue":"1","key":"2211_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-016-0123-3","volume":"4","author":"KM Beck","year":"2016","unstructured":"Beck KM, Dong J, Geskin LJ, Beltrani VP, Phelps RG, Carvajal RD et al (2016) Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid. J Immunother Cancer 4(1):1\u20135","journal-title":"J Immunother Cancer"},{"key":"2211_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/13543776.2018.1512706","volume":"28","author":"S Shaabani","year":"2018","unstructured":"Shaabani S, Huizinga HPS, Butera R, Kouchi A, Guzik K, Magiera-Mularz K et al (2018) A patent review on PD-1\/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015\u20132018). Expert Opin Ther Patents 28:665\u2013678","journal-title":"Expert Opin Ther Patents"},{"key":"2211_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3389\/fimmu.2020.01088","volume":"11","author":"Y Chen","year":"2020","unstructured":"Chen Y, Pei Y, Luo J, Huang Z, Yu J, Meng X (2020) Looking for the optimal PD-1\/PD-L1 inhibitor in cancer treatment: a comparison in basic structure, function, and clinical practice. Front Immunol 11:1088. https:\/\/doi.org\/10.3389\/fimmu.2020.01088","journal-title":"Front Immunol"},{"key":"2211_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/CMR.0000000000000189","volume":"26","author":"T Gambichler","year":"2016","unstructured":"Gambichler T, Scheitz R, H\u00f6xtermann S (2016) Serum anti-BPAG1 autoantibody level is not a useful biomarker for cutaneous melanoma. Melanoma Res 26:88\u201389","journal-title":"Melanoma Res"},{"issue":"1","key":"2211_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0022-1759(96)00167-6","volume":"199","author":"M Lu","year":"1996","unstructured":"Lu M, Thompson WA, Lawlor DA, Reveille JD, Lee JE (1996) Rapid direct determination of HLA-DQB1 * 0301 in the whole blood of normal individuals and cancer patients by specific polymerase chain reaction amplification. J Immunol Methods 199(1):61\u201368","journal-title":"J Immunol Methods"},{"issue":"1","key":"2211_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1399-0039.1998.tb03025.x","volume":"52","author":"AC Bateman","year":"1998","unstructured":"Bateman AC, Turner SJ, Theaker JM, Howell WM (1998) HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antigens 52(1):67\u201373","journal-title":"Tissue Antigens"},{"issue":"12","key":"2211_CR27","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1172\/JCI3335","volume":"102","author":"L B\u00fcdinger","year":"1998","unstructured":"B\u00fcdinger L, Borradori L, Yee C, Eming R, Ferencik S, Grosse-Wilde H et al (1998) Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Investig 102(12):2082\u20132089","journal-title":"J Clin Investig"},{"key":"2211_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/tan.12960","volume":"89","author":"KT Amber","year":"2017","unstructured":"Amber KT, Zikry J, Hertl M (2017) A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading? Hla 89:127\u2013134","journal-title":"Hla"},{"key":"2211_CR29","doi-asserted-by":"crossref","unstructured":"H\u00f6fler M (2005) The Bradford Hill considerations on causality: a counterfactual perspective. Emerg Themes Epidemiol [Internet] 2:11. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=1291382&tool=pmcentrez&rendertype=abstract","DOI":"10.1186\/1742-7622-2-11"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02211-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-021-02211-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02211-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T18:06:59Z","timestamp":1641578819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-021-02211-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2211"],"URL":"https:\/\/doi.org\/10.1007\/s00403-021-02211-4","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"2 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ADC served as an advisor, investigator, or speaker for Abbvie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer, and Rafa. None of the other authors have any conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}